Lipid nanoparticles (LNPs) are currently the most promising clinical nucleic acids drug
delivery vehicles. LNPs prevent the degradation of cargo nucleic acids during blood …

Lipid nanoparticles (LNPs) are the most versatile and successful gene delivery systems,
notably highlighted by their use in vaccines against COVID-19. LNPs have a well-defined …

Lipid nanoparticles (LNPs) containing ionizable aminolipids are among the leading
platforms for the successful delivery of nucleic-acid-based therapeutics, including …

In 2018, LNPs enabled the first FDA approval of a siRNA drug (Onpattro); two years later,
two SARS-CoV-2 vaccines (Comirnaty, Spikevax) based on LNPs containing mRNA also …

Climate change and the need for sustainable, technological developments are the greatest
challenges facing humanity in the coming decades. To address these issues, in 2015 the …

The covalent modification of proteins with polymers is a well-established method for
improving the pharmacokinetic properties of therapeutically valuable biologics. The …

The properties of mRNA lipid nanoparticles (mRNA-LNPs), including size, empty particles,
morphology, storage stability, and transfection potency, are critically dependent on the …

mRNA vaccines have emerged as a pivotal tool in combating COVID-19, offering an
advanced approach to immunization. A key challenge with these vaccines is their need for …

RNA-based therapies have shown promise in a wide range of applications, from cancer
therapy, treatment of inherited diseases to vaccination. Encapsulation of RNA into ionizable …

Lipid nanoparticles (LNP) have emerged as pivotal delivery vehicles for RNA therapeutics.
Previous research and development usually assumed that LNPs are homogeneous in …